Journal of Dermatology最新文献

筛选
英文 中文
Correction to “Automatic evaluation of nail psoriasis severity index using deep learning algorithm” 对 "利用深度学习算法自动评估指甲银屑病严重程度指数 "的更正。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-26 DOI: 10.1111/1346-8138.17556
{"title":"Correction to “Automatic evaluation of nail psoriasis severity index using deep learning algorithm”","authors":"","doi":"10.1111/1346-8138.17556","DOIUrl":"10.1111/1346-8138.17556","url":null,"abstract":"<p>Paik K, Kim BR, Youn SW. Automatic evaluation of nail psoriasis severity index using deep learning algorithm. <i>J Dermatol</i> 2024 Oct;51:1310–1317.</p><p>We apologize for this error.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 1","pages":"187"},"PeriodicalIF":2.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17556","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Educational video assistance in shared decision-making for psoriasis: Effectiveness and outcomes 银屑病共同决策中的教育视频辅助:效果和结果。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-25 DOI: 10.1111/1346-8138.17550
Sheng-Wen Liu, Shou En Wu, Yi-Hsien Chen, Chen-Yeu Soong, Chien-Ping Chiang, Wei-Ming Wang, Chih-Tsung Hung
{"title":"Educational video assistance in shared decision-making for psoriasis: Effectiveness and outcomes","authors":"Sheng-Wen Liu,&nbsp;Shou En Wu,&nbsp;Yi-Hsien Chen,&nbsp;Chen-Yeu Soong,&nbsp;Chien-Ping Chiang,&nbsp;Wei-Ming Wang,&nbsp;Chih-Tsung Hung","doi":"10.1111/1346-8138.17550","DOIUrl":"10.1111/1346-8138.17550","url":null,"abstract":"<p>Psoriasis is a chronic inflammatory skin condition associated with significant comorbidities that impact quality of life. Effective patient engagement through shared decision-making (SDM) is crucial for optimal management. This study aimed to evaluate the effectiveness of adding clinician-created educational videos in enhancing patient knowledge and engagement during SDM for psoriasis treatment. Forty-eight patients with moderate to severe psoriasis participated in this single-center study. After reading an educational pamphlet, patients took a knowledge assessment test. Subsequently, they watched an educational video and completed a second test using the same questions. Feedback questionnaires on the video and the SDM process were also administered. Paired <i>t</i> tests revealed that postpamphlet plus video test scores (mean ± SD: 86.25 ± 17.58) were significantly higher than postpamphlet scores (72.08 ± 26.33, <i>p</i> &lt; 0.0001). Older patients, in particular, showed greater improvement in comprehension after watching the video. Descriptive analysis of the feedback questionnaire on the video indicated strong agreement (average score: 4.240 ± 0.816 on a five-point Likert scale) regarding its greater effectiveness compared with the pamphlet in aiding SDM. Patients also rated the video-assisted SDM process positively (average score: 4.521 ± 0.5443 on a five-point Likert scale), highlighting increased trust and improved communication with healthcare providers. These findings underscore the value of video-assisted SDM in patient education and decision-making processes, potentially improving treatment outcomes and patient satisfaction in dermatologic care.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"337-343"},"PeriodicalIF":2.9,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutaneous lupus erythematosus following immunoglobulin therapy in dermatomyositis 皮肌炎患者接受免疫球蛋白治疗后出现皮肤红斑狼疮。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-25 DOI: 10.1111/1346-8138.17553
Eaman Alhassan, Stratos Christianakis, Brittney DeClerck, Ashley B. Crew
{"title":"Cutaneous lupus erythematosus following immunoglobulin therapy in dermatomyositis","authors":"Eaman Alhassan,&nbsp;Stratos Christianakis,&nbsp;Brittney DeClerck,&nbsp;Ashley B. Crew","doi":"10.1111/1346-8138.17553","DOIUrl":"10.1111/1346-8138.17553","url":null,"abstract":"<p>A 57-year-old woman with a remote history of follicular lymphoma in remission, treated with rituximab with subsequent diagnosis of hypogammaglobulinemia, presented to the Rheumatology-Dermatology clinic for evaluation of an autoimmune disease. The patient reported experiencing rash, myalgias, and proximal muscle weakness for 3 months. Physical examination was remarkable for poikiloderma over the neck and chest (V-sign), upper back (shawl sign), upper arms (sleeve sign), and lateral thighs (Holster sign). She had normal muscle strength. Laboratory work-up demonstrated normal complete blood count, comprehensive metabolic panel, creatine kinase, and aldolase levels. A myositis-specific antibody panel and antinuclear antibody tests were negative. The patient was diagnosed with amyopathic dermatomyositis. Because of her lymphoma history and skin-predominant presentation, intravenous immunoglobulin (Ig) therapy was administered. Three days after receiving the Ig therapy, the patient developed distinct, well-defined, violaceous, juicy appearing plaques on her face, chest, abdomen (Figure 1a), back (Figure 1b), and arms. Ig therapy was held. Skin biopsy of the new lesions showed interface dermatitis (Figure 1c) with increased dermal mucin and karyorrhectic debris consistent with discoid lupus erythematosus. Oral and topical corticosteroids were added with improvement in her skin lesions (Figure 1d).</p><p>A causative link between Ig G treatment and cutaneous lupus erythematosus has been reported in patients receiving Ig treatment for chronic inflammatory demyelinating polyneuropathy.<span><sup>1, 2</sup></span> The rash has been reported to improve after discontinuing Ig treatment or switching to another Ig brand. Van der Molen et al. reported the possible presence of Sjögren's-syndrome-related antigen (SSA) antibodies in Ig preparations.<span><sup>3</sup></span> While the mechanism of induction of cutaneous lupus erythematosus in patients being treated with Ig therapy is not well understood, one hypothesis is that the presence of SSA antibodies in Ig therapy may induce cutaneous lupus in a manner similar to cutaneous changes in neonatal lupus.</p><p>The authors declare no conflict of interest related to this work.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"e143-e144"},"PeriodicalIF":2.9,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations in RASA1 and EPHB4 in Chinese patients with capillary malformation-arteriovenous malformation 中国毛细血管畸形-动静脉畸形患者中 RASA1 和 EPHB4 的变异。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-22 DOI: 10.1111/1346-8138.17549
Qin Zeng, Wenmin Lu, Ying Ye, Ming Li, Hongsong Ge, Qiaoyu Cao, Wei He, Cheng Zhang, Wei Song
{"title":"Variations in RASA1 and EPHB4 in Chinese patients with capillary malformation-arteriovenous malformation","authors":"Qin Zeng,&nbsp;Wenmin Lu,&nbsp;Ying Ye,&nbsp;Ming Li,&nbsp;Hongsong Ge,&nbsp;Qiaoyu Cao,&nbsp;Wei He,&nbsp;Cheng Zhang,&nbsp;Wei Song","doi":"10.1111/1346-8138.17549","DOIUrl":"10.1111/1346-8138.17549","url":null,"abstract":"<p>Capillary malformation-arteriovenous malformation (CM-AVM) is a genetic condition predominantly attributed to variations in the <i>RASA1</i> or <i>EPHB4</i> genes. We identified three genetic variations: a variation in the RASA1 (c.2603+1G&gt;A) and two novel variations in the EPHB4 (c.53-2A&gt;G and c.2222T&gt;C), expanding the spectrum of variants associated with CM-AVM. Additionally, we found that the presence of EPHB4 variations in these two families, alongside a documented history of Bier spots, highlights the impact of genetic factors on disease phenotype. We also conducted 595 nm pulsed dye laser therapy on the proband 2, and observed that facial telangiectasia was significantly reduced after the laser treatment. We aim to enhance the understanding of the disease through case studies of three families.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"377-382"},"PeriodicalIF":2.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142694081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of notalgia paresthetica presenting as an ulcer successfully treated with gabapentin 一例以溃疡为表现的痛觉神经痛患者成功接受了加巴喷丁治疗。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-22 DOI: 10.1111/1346-8138.17558
Cheney Jianlin Wong, Harumi Ochi, Wei Liang Koh
{"title":"A case of notalgia paresthetica presenting as an ulcer successfully treated with gabapentin","authors":"Cheney Jianlin Wong,&nbsp;Harumi Ochi,&nbsp;Wei Liang Koh","doi":"10.1111/1346-8138.17558","DOIUrl":"10.1111/1346-8138.17558","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 1","pages":"e3-e4"},"PeriodicalIF":2.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142694077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of non-IgA vasculitis: Demographic, clinical, and treatment-related features in a retrospective analysis of 28 biopsy-confirmed cases from a German university hospital 非 IgA 血管炎的特征:对德国一所大学医院的 28 例活检确诊病例进行的回顾性分析中的人口统计学、临床和治疗相关特征。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1111/1346-8138.17545
Inga Hansen-Abeck, Alessandra Rünger, Lisa Piepke, Julian Kött, Anna Giordano-Rosenbaum, Anne Menz, Finn Abeck, Stefan W. Schneider
{"title":"Characterization of non-IgA vasculitis: Demographic, clinical, and treatment-related features in a retrospective analysis of 28 biopsy-confirmed cases from a German university hospital","authors":"Inga Hansen-Abeck,&nbsp;Alessandra Rünger,&nbsp;Lisa Piepke,&nbsp;Julian Kött,&nbsp;Anna Giordano-Rosenbaum,&nbsp;Anne Menz,&nbsp;Finn Abeck,&nbsp;Stefan W. Schneider","doi":"10.1111/1346-8138.17545","DOIUrl":"10.1111/1346-8138.17545","url":null,"abstract":"<p>Non-IgA vasculitis is a rare disease that belongs to the group of small-vessel vasculitides. Due to nomenclature and classification changes introduced in 2018, there are few published data under this name. The aim of this study is to characterize non-IgA vasculitis as an independent vasculitis entity in terms of demographic, clinical, and treatment-related features. A retrospective data analysis of patients with biopsy-confirmed non-IgA vasculitis treated at the Department of Dermatology at the University Medical Center Hamburg-Eppendorf between January 1, 2018, and December 31, 2022, was performed. A total of 28 patients with non-IgA vasculitis were included; 53.6% (15/28) were women and 42.9% (12/28) were older than 71 years. Previous infection as a possible triggering factor was found in 42.6% (12/28) of the cases. Palpable purpura was the most common skin finding (78.6%, 22/28) and 28.6% patients (8/28) had skin lesions above the waist. On direct immunofluorescence, C3 (89.3%, 25/28) was the most frequent deposition, followed by fibrinogen (71.4%, 20/28) and IgM (53.6%, 15/28). Hospitalization was required in 85.7% (24/28), with a mean hospital stay of 9.4 ± 4.1 days. No fatal courses were reported. This study is the first characterization of non-IgA vasculitis based on patient cases from Germany and contributes to a better understanding of non-IgA vasculitis as an independent entity. Non-IgA vasculitis primarily affects older patients of both sexes, with most cases having an identifiable trigger. Our results indicate that cutaneous manifestations often extend beyond the lower legs. Treatment is usually required in the inpatient setting and requires a longer stay than other dermatological conditions. With proper treatment, the disease is not expected to be fatal.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 1","pages":"43-49"},"PeriodicalIF":2.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17545","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignancies in patients with psoriasis during and after biological therapy: A single-center experience 银屑病患者在接受生物治疗期间和之后发生恶性肿瘤:单中心经验。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-16 DOI: 10.1111/1346-8138.17554
Hiroyuki Sakai, Masako Minami-Hori, Shiro Kuwahara
{"title":"Malignancies in patients with psoriasis during and after biological therapy: A single-center experience","authors":"Hiroyuki Sakai,&nbsp;Masako Minami-Hori,&nbsp;Shiro Kuwahara","doi":"10.1111/1346-8138.17554","DOIUrl":"10.1111/1346-8138.17554","url":null,"abstract":"<p>Over a 14-year period from 2010 to 2023, we treated 86 psoriasis patients with various biological agents at Asahikawa City Hospital, and 12 malignancies occurred in 11 of the patients. The numbers of malignancies by organ were as follows: four urogenital, three hematological, two gastrointestinal, one breast, one thyroid, and one lung. In two patients without cancer-related symptoms, elevated serum Krebs von den Lungen-6 levels led to the detection of intrahepatic cholangiocarcinoma or thyroid cancer, and they did not have interstitial lung disease. Dermatologists should be aware of the increased incidence of malignancy in patients with psoriasis requiring treatment with biologics.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"383-386"},"PeriodicalIF":2.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142645315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Epstein–Barr virus on macrophage M2/M1 migration and EphA2 expression in adverse drug reactions Epstein-Barr 病毒对药物不良反应中巨噬细胞 M2/M1 迁移和 EphA2 表达的影响。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-13 DOI: 10.1111/1346-8138.17496
Ran An, Dong-Jie Sun, Hao-Xue Lei, Ang-Ran He, Ying Tu, Jun-Ting Tang
{"title":"Effect of Epstein–Barr virus on macrophage M2/M1 migration and EphA2 expression in adverse drug reactions","authors":"Ran An,&nbsp;Dong-Jie Sun,&nbsp;Hao-Xue Lei,&nbsp;Ang-Ran He,&nbsp;Ying Tu,&nbsp;Jun-Ting Tang","doi":"10.1111/1346-8138.17496","DOIUrl":"10.1111/1346-8138.17496","url":null,"abstract":"&lt;p&gt;This study aims to investigate the effect of Epstein–Barr virus (EBV) reactivation or EBV reactivation with dexamethasone (DXM) in patients with adverse drug reactions (ADRs) through evaluating the levels of monocyte, macrophage M2/M1, and cytokines, and investigating whether expression of EBV receptor EphA2 could specifically influence EBV activation in ADRs. We performed a prospective longitudinal study to analyze the monocytes, macrophages, M2/M1 ratio, and cytokines, including interleukin (IL)-4, IL-13, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IFN-β, C-X-C motif chemokine ligand (CXCL)9, and CXCL10, in patients with maculopapular exanthema (MPE) and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and control groups after disease onset. Skin biopsy samples from these patients were subjected to hematoxylin and eosin (H&amp;E) staining to examine tissue architecture and inflammatory cell infiltration, as well as Epstein–Barr virus-encoded RNA (EBER) staining to detect the presence of EBV within the skin lesions. Peripheral blood mononuclear cells collected from these patients were co-cultured with EBV or EBV combined with DXM to assess the impact on monocytes, macrophages, the M2/M1 ratio, and the associated cytokine profile. Furthermore, we sought to identify which cytokines might be crucial in mediating the interaction between the M2/M1 ratio and EBV. EPhA2 expression was evaluated to determine its role in the reactivation of EBV and its correlation with increased viral load in MPE and SJS/TEN patients. Selective depletion of macrophages occurred during the acute stage of SJS/TEN, while a shift towards M2 macrophages was observed in MPE. Both IFN-β and CXCL9 levels were elevated in MPE and SJS/TEN. Additionally, our study demonstrated the presence of EBV in the skin lesions of SJS/TEN and MPE patients through H&amp;E and EBER staining, confirming EBV's involvement in these conditions. Activation of EBV and EBV combined with DXM led to a shift from M1 to M2 macrophages, accompanied by increased levels of IL-4, IFN-γ, and CXCL9 in MPE and SJS/TEN, compared to healthy individuals. Specifically, EBV combined with DXM primarily drove IFN-γ and IL-4 expansions in MPE, while CXCL9 was predominantly elevated in SJS/TEN. The increased IL-4 levels were associated with the relative rise in EBV viral loads after EBV combined with DXM stimulation. Furthermore, EphA2 expression in monocytes was significantly higher in SJS/TEN and MPE patients compared to controls, with further increases on EBV stimulation. This elevation in EPhA2 correlated with increased EBV viral load, particularly in MPE and SJS/TEN patients. The gradual shift from M1 to M2 cell development observed during the clinical course of MPE and SJS/TEN is mediated by the predominance of EBV and EBV with DXM at the acute stage, leading to elevated IL-4, IFN-γ, and CXCL9 levels, which may exacerbate allergic reactions. The elevation in EPhA2 correlated with increased EB","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 1","pages":"87-96"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in Japan 阿达木单抗对脓疱疮患者的实际安全性和有效性:日本一项上市后观察研究的中期分析。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-13 DOI: 10.1111/1346-8138.17547
Toshiyuki Yamamoto, Keiichi Yamanaka, Kenshi Yamasaki, Hisaaki Isaji, Naoko Matsubara, Hiroyuki Hozawa, Tamihiro Kawakami
{"title":"Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in Japan","authors":"Toshiyuki Yamamoto,&nbsp;Keiichi Yamanaka,&nbsp;Kenshi Yamasaki,&nbsp;Hisaaki Isaji,&nbsp;Naoko Matsubara,&nbsp;Hiroyuki Hozawa,&nbsp;Tamihiro Kawakami","doi":"10.1111/1346-8138.17547","DOIUrl":"10.1111/1346-8138.17547","url":null,"abstract":"<p>Pyoderma gangrenosum (PG) is a rapidly progressive disease characterized by deep ulcers, predominantly in the lower extremities. Adalimumab, a monoclonal antibody against tumor necrosis factor alpha, is the first drug approved for PG treatment in Japan, ahead of other countries. We conducted a multicenter, open-label, post-marketing observational study to evaluate the safety and effectiveness of adalimumab in Japanese patients with PG. Of 67 patients enrolled, 37 in the safety analysis set and 32 in the effectiveness analysis set were included in this interim analysis. (Nineteen patients whose case report forms were not collected and 11 whose data were not fixed by the data cut-off date were excluded from the study). In the safety analysis set, the mean age was 62.9 years and 86.5% of patients had comorbidities, including ulcerative colitis (21.6%), diabetes mellitus (18.9%), and hypertension (10.8%); subtypes of PG included ulcerative (<i>n</i> = 33), vegetative (<i>n</i> = 2), and pustular (<i>n</i> = 2). Mean exposure duration to adalimumab was 185.5 days. Systemic steroids were used before (70.3%) and during (56.8%) adalimumab treatment. The incidence proportion of overall adverse drug reactions was 18.9%. The incidence proportions of all infections and serious infections reported as adverse drug reactions were 13.5% and 10.8%, respectively. The proportion of patients with a Physician Global Assessment score (total lesions) of 0/1 at weeks 12, 26, and 52 was 42.9%, 36.8%, and 50.0%, respectively. This interim analysis revealed the characteristics of Japanese patients with PG treated with adalimumab in the actual clinical setting and the real-world safety and effectiveness of adalimumab. At the time of the interim analysis, adalimumab treatment was generally well tolerated, and no new safety concerns were detected. Further follow-up of this study will provide a more detailed understanding of the long-term safety and effectiveness of adalimumab in patients with PG refractory to conventional treatments.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"270-280"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17547","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series 彭博利珠单抗联合化疗宫颈癌期间的延迟和即刻皮肤不良事件:病例系列。
IF 2.9 3区 医学
Journal of Dermatology Pub Date : 2024-11-11 DOI: 10.1111/1346-8138.17521
Takeya Adachi, Tomoya Matsui, Utako Okata-Karigane, Chiaki Takahashi, Umi Tahara, Mari Hyodo, Akihiro Miyagawa, Kenta Kobayashi, Yoshio Nakamura, Takeru Funakoshi, Hiroshi Nishio, Wataru Yamagami, Hayato Takahashi
{"title":"Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series","authors":"Takeya Adachi,&nbsp;Tomoya Matsui,&nbsp;Utako Okata-Karigane,&nbsp;Chiaki Takahashi,&nbsp;Umi Tahara,&nbsp;Mari Hyodo,&nbsp;Akihiro Miyagawa,&nbsp;Kenta Kobayashi,&nbsp;Yoshio Nakamura,&nbsp;Takeru Funakoshi,&nbsp;Hiroshi Nishio,&nbsp;Wataru Yamagami,&nbsp;Hayato Takahashi","doi":"10.1111/1346-8138.17521","DOIUrl":"10.1111/1346-8138.17521","url":null,"abstract":"<p>Immune checkpoint inhibitors (ICIs), such as pembrolizumab (PEM), are widely recognized for their antitumor efficacy, but they can also lead to various cutaneous adverse events (CAEs). While most CAEs can be managed with topical corticosteroids, severe cases may necessitate halting immunotherapy. The incidence of severe CAEs is notably higher in combination therapies involving ICIs than in monotherapies, emphasizing the need for stringent, long-term management strategies. This includes potential modifications or discontinuations of the combination therapy. PEM, when added to the conventional paclitaxel + cisplatin (or carboplatin) ± bevacizumab regimen, has shown significant improvements in overall and progression-free survival for patients with Stage IVB metastatic or locally uncontrolled recurrent cervical cancer. This case series retrospectively examined the incidence and management of CAEs in 19 female patients treated with this combination therapy between October 2022 and May 2023. Four patients exhibiting CTCAE grade 3 were identified. The four cases of severe CAEs involved erythema multiforme after the initial course of PEM combination chemotherapy. Notably, three patients experienced immediate hypersensitivity reactions, including anaphylaxis, during subsequent treatments. This observation underscores the necessity for rigorous dermatological monitoring of patients undergoing PEM combination chemotherapy. Such vigilance is crucial for early detection of adverse reactions and timely adjustment of treatment regimens, thereby enhancing patient safety.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 1","pages":"132-137"},"PeriodicalIF":2.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信